SheMed partners with Tasso to personalise GLP-1 treatment for women

Medtech company Tasso, Inc. and SheMed, a UK-based women’s healthcare company, have announced a new partnership aimed at delivering safer, more personalised weight loss treatments through at-home diagnostics.

SheMed’s testing programme, which integrates the Tasso+ blood collection device, ensures that every patient completes a comprehensive lab screening before starting GLP-1 treatment.

For decades, women have been underrepresented in clinical trials.

As a result, many treatments have been developed based on male physiology, leading to a one-size-fits-all approach that often overlooks women’s specific health needs.

Although GLP-1s have transformed the weight loss landscape, many women begin treatment without a full picture of their underlying health, increasing the risk of complications and limiting results.

Olivia Ferro, CEO of SheMed, said: “For too long, women have been left out of the conversation when it comes to clinical care.

“At SheMed, our mission is to empower women to take control of their health through safe, accessible, and personalised treatment.

“Tasso gives our customers access to high-quality at-home blood testing, allowing us to deliver care that meets women where they are.”

At SheMed, every patient begins their treatment journey with Tasso’s virtually painless, lancet-based device.

The sample collection process takes less than five minutes and eliminates the need for clinic visits – an important factor, as a recent survey found that 78 per cent of patients report anxiety around traditional blood draws and 69 percent say they would not travel more than 10 miles for testing.

This blood test is central to SheMed’s care model and results reveal key health markers such as diabetes risk, cardiovascular health, liver function and thyroid activity.

These insights allow SheMed’s care team to detect early health issues, personalise each treatment plan, track progress over time and deliver safer, more effective GLP-1 therapy.

Ben Casavant, PhD, CEO and Co-Founder of Tasso, Inc., said: “Simplifying blood collection and expanding patient access to essential health data is at the core of our mission at Tasso.

“Our UK collaboration with SheMed is a powerful example of how patient-centric innovation can close long-standing gaps in care and give individuals more control over their health.”